В настоящее время в Казахстане регу

В настоящее время в Казахстане регулируются цены только на те лекарства, которые закупаются для нужд ГОБМП. В конце июля вышел приказ, в котором правила формирования цен были детализированы с учетом реалий, система формирования цен стала более понятной и прозрачной. В частности, предельная цена теперь определяется как среднее арифметическое между зарегистрированными предельными ценами (а не оптовыми, как было ранее) торговых наименований лекарственных средств в разрезе одного МНН с учетом лекарственной формы и дозировки, закупаемых в рамках ГОБМП. Предельная цена включает оптовую надбавку не более 15%, а ранее она формировалась с учетом наценки единого дистрибьютора и индекса потребительских цен.

Для лекарственных средств, производимых отечественными предприятиями в условиях GMP и поставляемых в рамках долгосрочных договоров, заключенных до 1 января 2015 года, предельная цена стала определяться на основе цены фактического закупа предыдущего года, с учетом оптовой наценки, и ежегодно в течение последующих 5 лет, - снижаться на 5%.

Представленные на регистрацию цены анализируются уполномоченным органом посредством внутреннего и внешнего референтного ценообразования. И, если цена завышена, то проводятся переговоры с производителем или его законным представителем по ее обоснованию и возможному снижению. При несогласии сторон вопрос рассматривается Формулярной комиссией.

И, самое главное, в случае изменения официального курса тенге к доллару более чем на 15% при формировании предельных цен дополнительно учитывается коэффициент изменения курса тенге к доллару. Это очень важно с учетом сегодняшней экономической ситуации.

В целом, данная система ценообразования позволит более экономно и эффективно расходовать средства, выделяемые на закуп лекарств. Она дает возможность выполнить обязательства по поставкам лекарств в случае девальвации, а, значит, защищает пациентов от дефицита лекарств. Плохо лишь одно, что столь важный приказ разрабатывался непосредственно перед началом закупок, производителям пришлось в спешке предоставить предельные цены, а ведь их еще требовалось проанализировать, зарегистрировать и т.д.

Results (English) 1:

Currently, Kazakhstan is governed by prices only to those drugs that are purchased for the needs of GOBMP. At the end of July, left the order in which the pricing rules were further elaborated in the light of realities, the pricing system has become more comprehensible and transparent. In particular, the maximum price now is defined as the arithmetic mean between registered marginal prices (and not, as previously) trade names of medicines in the context of one INN in the light of the pharmaceutical form and dosage, procured under the GOBMP. The marginal price includes wholesale allowance of not more than 15%, and previously she was formed, taking into account the margins of a single Distributor and the consumer price index.For medicines produced by domestic enterprises in terms of GMP and supplied under long-term contracts concluded before January 1, 2015 year reserve price was the price determined on the basis of the actual purchase of the previous year, taking into account wholesale markups, and annually over the next 5 years, to decline by 5%.Submitted for registration prices analysed the notified body by means of internal and external reference pricing. And if the price is inflated, there will be negotiations with the manufacturer, or his legal representative on its justification and eventual decline. In case of disagreement the parties Menu is considered by the Commission.And, most importantly, in the case of change of a official rate of tenge against dollar by more than 15% when forming limit further price factor changes the rate of tenge against dollar. This is very important given the current economic situation.In General, this pricing system will allow more economically and efficiently expending funds for purchasing medicines. It gives an opportunity to fulfil the commitments on the supply of medicines in case of devaluation, and protects patients from lack of medication. Only one bad thing that such an important order was developed immediately prior to the commencement of the procurement, the producers had to hurriedly provide marginal rates, but they still needed to analyse, register, etc.

Results (English) 2:

Currently in Kazakhstan are regulated by prices only to those medicines that are purchased for the needs of SBP. In late July, there was an order in which the rules were detailed pricing taking into account the realities of the system of price formation has become more clear and transparent. In particular, the marginal price is now defined as the arithmetic mean between registered marginal costs (as opposed to wholesale, as it was earlier) trade names of drugs in the context of a single INN given formulation and dosage procured under SBP. Reserve price includes wholesale allowance of not more than 15%, while earlier it was formed taking into account the margin of a single distributor, and the consumer price index. For drugs produced by domestic enterprises under GMP conditions and delivered under long-term contracts concluded before 1 January 2015, the marginal price became determined based on the actual purchase price of the previous year, taking into account the wholesale mark-up, and each year over the next 5 years - to fall by 5%. The presented for registration rates are analyzed by the authorized body through the internal and external reference pricing. And if the price is too high, it held talks with the manufacturer or his legal representative for its validity and the possible reduction. In case of disagreement the parties is discussed Formulary Committee. And, most importantly, in the case of change of the official exchange rate of tenge to the dollar by more than 15% in the formation of price limits is further taken into account the rate of change of rate of tenge to the dollar. This is very important given the current economic situation. In general, this pricing system will allow more economically and efficiently use the funds allocated for the purchase of medicines. It provides an opportunity to fulfill obligations to supply drugs in the event of a devaluation, and thus protects the patient from a shortage of medicines. Poor but one that is so important orders developed immediately prior to procurement, manufacturers had rushed to provide maximum prices, and yet they are also required to analyze, register, etc.

Results (English) 3:

Currently, in Kazakhstan are governed by price only to those drugs that are purchased for the needs ГОБМП. At the end of July has left an order, in which rules of prices were further elaborated in accordance with the realities,The system of prices has become more understandable and transparent. In particular, limit the price now is defined as the arithmetic mean between registered price limits (not bulk,As it was previously) trade names drugs in a cross-sectional view inn with the dosage form and dosage, purchased in the ГОБМП. Limit price includes wholesale allowance is not more than 15 %.